Sign In
Buy ATRA
$9.63
-0.270 (-2.73%)
At Close: Jun 03, 2026
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
12:00pm, Sunday, 26'th Jan 2025
NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ:ATRA). Such inve
Atara Biotherapeutics, Inc. (ATRA) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates
12:45pm, Friday, 24'th Jan 2025
NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Atara Biotherapeutics, Inc. ("Atara Biotherapeutics, Inc.") (NASDAQ:AT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
12:00pm, Friday, 24'th Jan 2025
NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ:ATRA). Such investors
NEW YORK, NY / ACCESS Newswire / January 24, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Atara Biotherapeutics, Inc. ("Atara Biotherapeutics, Inc.") (NASDAQ:AT
Atara Biotherapeutics, Inc. Being Investigated on Behalf of Atara Biotherapeutics, Inc. Investors. Contact Levi & Korsinsky For Details
01:30pm, Wednesday, 22'nd Jan 2025
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Atara Biotherapeutics, Inc. ("Atara Biotherapeutics, Inc.") (NASDAQ:AT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
01:00pm, Wednesday, 22'nd Jan 2025
NEW YORK CITY, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc.("Atara" or the "Company") (NASDAQ:ATRA). Such inves
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Atara Biotherapeutics, Inc. (ATRA)
11:15am, Wednesday, 22'nd Jan 2025
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Atara Biotherapeutics, Inc. ("Atara Biotherapeutics, Inc.") (NASDAQ:AT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
10:45am, Wednesday, 22'nd Jan 2025
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ:ATRA). Such investors
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Atara Biotherapeutics, Inc. (ATRA)
07:00pm, Tuesday, 21'st Jan 2025
NEW YORK, NY / ACCESS Newswire / January 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Atara Biotherapeutics, Inc. ("Atara Biotherapeutics, Inc.") (NASDAQ:AT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
06:25pm, Tuesday, 21'st Jan 2025
NEW YORK , Jan. 21, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA). Such investors are advis
FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs
01:11pm, Tuesday, 21'st Jan 2025
On Tuesday, the U.S. Food and Drug Administration (FDA) placed a clinical hold on Atara Biotherapeutics, Inc.'s ATRA active Investigational New Drug (IND) applications.
Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219
07:30am, Tuesday, 21'st Jan 2025
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell pl
Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues
12:21am, Tuesday, 21'st Jan 2025
Atara has just announced a CRL by FDA for EBVALLO. EBVALLO is already approved in Europe since December 2022 and the cause of the CRL seems minor and easily addressable. The CRL has a major impact on
NEW YORK CITY, NY / ACCESS Newswire / January 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Atara Biotherapeutics, Inc. ("Atara Biotherapeutics, Inc.") (NASD
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
08:55pm, Saturday, 18'th Jan 2025
NEW YORK, NY / ACCESS Newswire / January 18, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ: ATRA). Such investor
